OXFORD, Engeland–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) heeft vandaag aangekondigd dat Andrew Hopkins, DPhil., oprichter en CEO van Exscientia, en Dave Hallett, Chief Operations Officer, zullen deelnemen aan een gesprek bij het haardvuur tijdens de Goldman Sachs 43e jaarlijkse wereldwijde Healthcare Conference op dinsdag 14 juni 2022 om 9.20 uur P.T. (17:20 uur BST).

Een live webcast van de open haard-chat zal beschikbaar zijn op de website van het bedrijf, onder de sectie “Investors & Media” op www.investors.exscientia.ai. Een gearchiveerde herhaling van de webcast zal ongeveer 30 dagen na de presentatie beschikbaar zijn.

Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, and Dave Hallett, Chief Operations Officer, will participate in a fireside chat at the Goldman Sachs 43^rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 9:20 a.m. P.T. (5:20 p.m. BST).

A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606006030/en/

Contacts

Investors:
Sara Sherman

investors@exscientia.ai

Media:
Amanda Galgay

media@exscientia.ai